Literature DB >> 18646837

Synthesis and in vitro characterization of a dendrimer-MORF conjugate for amplification pretargeting.

Xiangji Chen1, Shuping Dou, Guozheng Liu, Xinrong Liu, Yi Wang, Ling Chen, Mary Rusckowski, Donald J Hnatowich.   

Abstract

Amplification pretargeting can play an important role in molecular imaging by significantly increasing the accumulation of signal in target tissues. Multiple-step amplification pretargeting offers the potential to greatly improve target localization of effector molecules through the intermediate use of polymers conjugated with multiple copies of complementary oligomers. In this study, PAMAM dendrimer generation 3 (G3) was conjugated with multiple copies of a phosphorodiamidate morpholino (MORF) oligomer. Characterization of the conjugate by native-PAGE and SE-HPLC demonstrated that the conjugation was successful. The average numbers of MORF groups in the G3-MORF conjugate, both attached and accessible to the (99m)Tc labeled complementary MORF (cMORF), were determined. The antitumor antibody CC49 was conjugated with both MORF and cMORF (collectively (c)MORF) at an average of about one group per molecule. Nine of the 32 carboxyl groups of the dendrimer were modified with MORF, of which 90% were accessible in solution to (99m)Tc-cMORF. After purification, the G3-MORF was radiolabeled with tracer (99m)Tc-labeled cMORF (i.e., G3-MORF/(99m)Tc-cMORF) and added to the antibody CC49 previously conjugated with cMORF (i.e., CC49-cMORF/G3-MORF/(99m)Tc-cMORF), the complex demonstrated a single peak on SE-HPLC as evidence of complete hybridization between G3-MORF/(99m)Tc-cMORF and CC49-cMORF. The CC49-(c)MORF were bound to both Protein G and Protein L coated plates, and G3-MORF was added to hybridize with CC49-cMORF before the (99m)Tc-cMORF was added to test amplification pretargeting. In comparison to conventional pretargeting without the G3-MORF, the signal was amplified about 6 and 14 times, respectively, showing that the G3-MORF participated in amplifying the signal. Further amplification studies using the CC49-(c)MORF for LS174T tumor cells in tissue culture also demonstrated clear evidence of signal amplification.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18646837      PMCID: PMC2574576          DOI: 10.1021/bc8001024

Source DB:  PubMed          Journal:  Bioconjug Chem        ISSN: 1043-1802            Impact factor:   4.774


  45 in total

1.  Design and function of a dendrimer-based therapeutic nanodevice targeted to tumor cells through the folate receptor.

Authors:  Antonio Quintana; Ewa Raczka; Lars Piehler; Inhan Lee; Andrzej Myc; Istvan Majoros; Anil K Patri; Thommey Thomas; James Mulé; James R Baker
Journal:  Pharm Res       Date:  2002-09       Impact factor: 4.200

2.  Dendritic iodinated contrast agents with PEG-cores for CT imaging: synthesis and preliminary characterization.

Authors:  Yanjun Fu; Danute E Nitecki; David Maltby; Gerhard H Simon; Kirill Berejnoi; Hans-Juergen Raatschen; Benjamin M Yeh; David M Shames; Robert C Brasch
Journal:  Bioconjug Chem       Date:  2006 Jul-Aug       Impact factor: 4.774

Review 3.  Molecular advances in pretargeting radioimunotherapy with bispecific antibodies.

Authors:  Chien-Hsing Chang; Robert M Sharkey; Edmund A Rossi; Habibe Karacay; William McBride; Hans J Hansen; Jean-François Chatal; Jacques Barbet; David M Goldenberg
Journal:  Mol Cancer Ther       Date:  2002-05       Impact factor: 6.261

4.  Biodegradable cystamine spacer facilitates the clearance of Gd(III) chelates in poly(glutamic acid) Gd-DO3A conjugates for contrast-enhanced MR imaging.

Authors:  Tianyi Ke; Yi Feng; Junyu Guo; Dennis L Parker; Zheng-Rong Lu
Journal:  Magn Reson Imaging       Date:  2006-05-26       Impact factor: 2.546

5.  The development of folate-PAMAM dendrimer conjugates for targeted delivery of anti-arthritic drugs and their pharmacokinetics and biodistribution in arthritic rats.

Authors:  Durairaj Chandrasekar; Ramakrishna Sistla; Farhan J Ahmad; Roop K Khar; Prakash V Diwan
Journal:  Biomaterials       Date:  2006-09-22       Impact factor: 12.479

6.  HER2 specific tumor targeting with dendrimer conjugated anti-HER2 mAb.

Authors:  Rameshwer Shukla; Thommey P Thomas; Jennifer L Peters; Ankur M Desai; Jolanta Kukowska-Latallo; Anil K Patri; Alina Kotlyar; James R Baker
Journal:  Bioconjug Chem       Date:  2006 Sep-Oct       Impact factor: 4.774

7.  Pretargeting with amplification using polymeric peptide nucleic acid.

Authors:  Y Wang; F Chang; Y Zhang; N Liu; G Liu; S Gupta; M Rusckowski; D J Hnatowich
Journal:  Bioconjug Chem       Date:  2001 Sep-Oct       Impact factor: 4.774

8.  Dendrimers: relationship between structure and biocompatibility in vitro, and preliminary studies on the biodistribution of 125I-labelled polyamidoamine dendrimers in vivo.

Authors:  N Malik; R Wiwattanapatapee; R Klopsch; K Lorenz; H Frey; J W Weener; E W Meijer; W Paulus; R Duncan
Journal:  J Control Release       Date:  2000-03-01       Impact factor: 9.776

9.  The influence of chain length and base sequence on the pharmacokinetic behavior of 99mTc-morpholinos in mice.

Authors:  G Liu; S Zhang; J He; N Liu; S Gupta; M Rusckowski; D J Hnatowich
Journal:  Q J Nucl Med       Date:  2002-09

10.  Synthesis and testing of a binary catalytic system for imaging of signal amplification in vivo.

Authors:  Alexei Bogdanov; Hye-Won Kang; Manuel Querol; P Hendrik Pretorius; Anna Yudina
Journal:  Bioconjug Chem       Date:  2007-05-18       Impact factor: 4.774

View more
  7 in total

Review 1.  Radioimmunotherapy of human tumours.

Authors:  Steven M Larson; Jorge A Carrasquillo; Nai-Kong V Cheung; Oliver W Press
Journal:  Nat Rev Cancer       Date:  2015-06       Impact factor: 60.716

Review 2.  Whither Radioimmunotherapy: To Be or Not To Be?

Authors:  Damian J Green; Oliver W Press
Journal:  Cancer Res       Date:  2017-04-20       Impact factor: 12.701

3.  Design and In Vitro Evaluation of Bispecific Complexes and Drug Conjugates of Anticancer Peptide, LyP-1 in Human Breast Cancer.

Authors:  Selin Seda Timur; Prashant Bhattarai; Reyhan Neslihan Gürsoy; İmran Vural; Ban-An Khaw
Journal:  Pharm Res       Date:  2016-11-28       Impact factor: 4.200

4.  Novel DNA Polymer for Amplification Pretargeting.

Authors:  Xiao Li; Qingqing Huang; Jie Xiao; Guozheng Liu; Shuping Dou; Mary Rusckowski; Hongcheng Shi; Yuxia Liu; Dengfeng Cheng
Journal:  ACS Med Chem Lett       Date:  2015-07-27       Impact factor: 4.345

5.  Comparative Analysis of Bispecific Antibody and Streptavidin-Targeted Radioimmunotherapy for B-cell Cancers.

Authors:  Damian J Green; Shani L Frayo; Yukang Lin; Donald K Hamlin; Darrell R Fisher; Sofia H L Frost; Aimee L Kenoyer; Mark D Hylarides; Ajay K Gopal; Theodore A Gooley; Johnnie J Orozco; Brian G Till; Shyril O'Steen; Kelly D Orcutt; D Scott Wilbur; K Dane Wittrup; Oliver W Press
Journal:  Cancer Res       Date:  2016-09-02       Impact factor: 12.701

6.  CD38-bispecific antibody pretargeted radioimmunotherapy for multiple myeloma and other B-cell malignancies.

Authors:  Damian J Green; Shyril O'Steen; Yukang Lin; Melissa L Comstock; Aimee L Kenoyer; Donald K Hamlin; D Scott Wilbur; Darrell R Fisher; Margaret Nartea; Mark D Hylarides; Ajay K Gopal; Theodore A Gooley; Johnnie J Orozco; Brian G Till; Kelly D Orcutt; K Dane Wittrup; Oliver W Press
Journal:  Blood       Date:  2017-11-20       Impact factor: 22.113

Review 7.  A semiempirical model of tumor pretargeting.

Authors:  Guozheng Liu; Donald J Hnatowich
Journal:  Bioconjug Chem       Date:  2008-11-19       Impact factor: 4.774

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.